50% off all subscriptions! ... left. Order NowOrder Now

Weaker Stock
Today CLRB ranks #12628 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Cellectar Biosciences Stock Forecast NASDAQ:CLRB

$0.72 (-3.61%)

Volume: 198k

Closed: Nov 26, 2021

Hollow Logo Score: -5.203

Cellectar Biosciences Stock Forecast

$0.72 (-3.61%)

Volume: 198k

Closed: Nov 26, 2021

Score Hollow Logo -5.203
Which way will CLRB go? Request
Key Stats
Beta 0.55
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] The Cellectar Biosciences stock currently holds an RSI14 at 22 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.

Weaker technical forecast for Cellectar Biosciences as stock downgraded to Strong Sell Candidate.
(Updated on Nov 26, 2021)


Sell candidate since 2021-11-09 Loss -20.83%

The Cellectar Biosciences stock price fell by -3.61% on the last day (Friday, 26th Nov 2021) from $0.75 to $0.72. During the day the stock fluctuated 7.11% from a day low at $0.70 to a day high of $0.75. The price has fallen in 6 of the last 10 days and is down by -16.37% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -20 thousand shares and in total, 198 thousand shares were bought and sold for approximately $143.29 thousand.

The stock has broken the very wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($0.73) are considered to be a "second chance" to get out. According to the fan-theory $0.49 will represent the new bottom line of the next trend, but it is far too early to say this for certain.

Signals & Forecast

There are few to no technical positive signals at the moment. The Cellectar Biosciences stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $0.76 and $0.87. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, November 04, 2021, and so far it has fallen -29.13%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0498 between high and low, or 7.11%. For the last week the stock has had a daily average volatility of 9.39%.

Cellectar Biosciences is oversold on RSI14 (22). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Cellectar Biosciences stock A Buy?

Cellectar Biosciences holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -5.203

Predicted Opening Price for Cellectar Biosciences of Monday, November 29, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price November 29, 2021 Current price
$0.72 $0.72 (Undervalued)
Strong Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Aug 10, 2021 "HC Wainwright" gave "$3.00" rating for CLRB. The price target was changed from $1.00 to 1.0%.

Volatility and Risk
Daily Average Volatility: 9.39 %
Overall Risk: Very High High Medium Low Very Low
Volatility
9.39 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $0.77
Price: $0.72
No Support Found

CLRB Insider Trading Show all Trades

INSIDER POWER

11.395

Last 100 transactions
Buy: 7 790 897 | Sell: 683 686 (Shares)
Date Action Amount Person Type
Sep 14, 2021 Buy 25 000 Swirsky Douglas J Common Stock
Sep 03, 2021 Buy 19 417 Driscoll Frederick W Common Stock
Jun 30, 2021 Buy 78 000 Chanan-khan Asher Stock option (right to buy)
Jun 30, 2021 Buy 78 000 Loren Stefan Stock option (right to buy)
Jun 30, 2021 Buy 78 000 Driscoll Frederick W Stock option (right to buy)
Show all Insider Trades
INSIDER POWER

11.395

Last 100 transactions
Buy: 7 790 897 | Sell: 683 686 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 0.77 7.09 %
0.76 4.46 %
0.74 2.83 %
Current price: 0.72
Support 0.71 -2.43 %
0.69 -4.05 %
0.67 -6.69 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0.86 19.26 %
0.80 10.80 %
0.77 6.22 %
Current price 0.72
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Cellectar Biosciences

Cellectar Biosciences Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate and is currently being evaluated in a Phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT